[go: up one dir, main page]

TW221994B - - Google Patents

Info

Publication number
TW221994B
TW221994B TW081108539A TW81108539A TW221994B TW 221994 B TW221994 B TW 221994B TW 081108539 A TW081108539 A TW 081108539A TW 81108539 A TW81108539 A TW 81108539A TW 221994 B TW221994 B TW 221994B
Authority
TW
Taiwan
Application number
TW081108539A
Original Assignee
Glaxo Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Spa filed Critical Glaxo Spa
Application granted granted Critical
Publication of TW221994B publication Critical patent/TW221994B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
TW081108539A 1991-10-29 1992-10-27 TW221994B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78427591A 1991-10-29 1991-10-29
US82672992A 1992-01-28 1992-01-28

Publications (1)

Publication Number Publication Date
TW221994B true TW221994B (zh) 1994-04-01

Family

ID=27120258

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081108539A TW221994B (zh) 1991-10-29 1992-10-27

Country Status (25)

Country Link
EP (1) EP0540099B1 (zh)
JP (2) JP3020760B2 (zh)
KR (1) KR100246154B1 (zh)
CN (1) CN1072683A (zh)
AP (1) AP306A (zh)
AT (1) ATE136898T1 (zh)
AU (1) AU657007B2 (zh)
CA (1) CA2081580A1 (zh)
CZ (1) CZ284023B6 (zh)
DE (1) DE69209969T2 (zh)
DK (1) DK0540099T3 (zh)
ES (1) ES2086643T3 (zh)
FI (3) FI104373B (zh)
GR (1) GR3020120T3 (zh)
HU (2) HU217970B (zh)
IL (1) IL103571A (zh)
IS (1) IS1708B (zh)
MX (1) MX9206211A (zh)
MY (1) MY108261A (zh)
NO (1) NO302073B1 (zh)
NZ (1) NZ244914A (zh)
OA (1) OA09767A (zh)
RU (1) RU2119921C1 (zh)
SK (1) SK323792A3 (zh)
TW (1) TW221994B (zh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364858A (en) * 1987-03-31 1994-11-15 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
AP9300587A0 (en) * 1992-11-12 1995-05-05 Glaxo Inc Water soluble camptothecin derivatives.
DK1250926T3 (da) * 1993-01-15 2008-07-07 Stehlin Foundation For Cancer Anvendelse af vanduoplöseligt S-camptothecin med en lukket lactonring i fremstilling af et medikament til behandling af coloncancer
US5369127A (en) * 1993-04-21 1994-11-29 Allergan, Inc. 1,3-benzodioxole and 1,2-dialkoxybenzene derivatives as ocular hypotensive agents
IS4152A (is) * 1993-04-29 1994-10-30 Glaxo Inc. Vatnsuppleysanlegar Camptothecin afleiður og aðferð til framleiðslu þeirra
EP0699201A1 (en) * 1993-05-03 1996-03-06 Smithkline Beecham Corporation SUBSTITUTED METHYLENEDIOXY 3',4':6,7]INDOLIZINO- 1,2-$i(b)]QUINOLINONES
US5447936A (en) * 1993-12-22 1995-09-05 Bionumerik Pharmaceuticals, Inc. Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin and methods for uses thereof
US5491237A (en) * 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
IT1269862B (it) * 1994-05-30 1997-04-15 Indena Spa Alcaloidi da mappia foetida, loro uso e formulazioni che li contengono
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
KR960029336A (ko) * 1995-01-09 1996-08-17 김충환 캄토테신 유도체, 그의 제조 방법 및 이를 함유하는 항암제
US5496952A (en) * 1995-02-07 1996-03-05 North Carolina State University Method of making asymmetric DE ring intermediates for the synthesis of camptothecin and camptothecin analogs
US5670500A (en) * 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
EP0837850B1 (en) * 1995-06-27 2004-09-01 Takeda Chemical Industries, Ltd. 4-acylamino(halogeno) alkyl-quinoline derivatives, their preparation and their use as melatonin agonists
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
WO1997019085A1 (en) * 1995-11-22 1997-05-29 Research Triangle Institute Camptothecin compounds with combined topoisomerase i inhibition and dna alkylation properties
CA2192725C (en) 1995-12-28 2004-04-20 Kenji Tsujihara Camptothecin derivatives
SG104284A1 (en) * 1996-10-30 2004-06-21 Tanabe Seiyaku Co S type 2-substituted hydroxy-2-indolidinylbutyric ester compounds and process for preparation thereof
US6559309B2 (en) * 1996-11-01 2003-05-06 Osi Pharmaceuticals, Inc. Preparation of a camptothecin derivative by intramolecular cyclisation
US6207673B1 (en) 1997-03-12 2001-03-27 The University Of North Carolina At Chapel Hill Covalent conjugates of topoisomerase I and topoisomerase II inhibitors
US6046209A (en) * 1997-05-27 2000-04-04 Smithkline Beecham Corporation Water soluble camptothecin analogs
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
CA2401191C (en) 2000-02-28 2006-05-02 Aventis Pharma S.A. A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
US6548488B2 (en) 2000-03-17 2003-04-15 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and an alkylating agent for the treatment of cancer
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
US6486320B2 (en) 2000-09-15 2002-11-26 Aventis Pharma S.A. Preparation of camptothecin and of its derivatives
CN1200712C (zh) 2000-10-27 2005-05-11 阿文蒂斯药物股份有限公司 用于治疗癌症的含喜树碱和1,2－二苯乙烯衍生物的组合物
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
US20090104254A1 (en) 2004-12-22 2009-04-23 Rutgers, The State University Of New Jersey Controlled Release Hydrogels
AU2007232206B2 (en) 2006-03-30 2013-04-04 Drais Pharmaceuticals, Inc. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
CN101407524B (zh) * 2007-10-09 2012-07-18 江苏先声药物研究有限公司 噁嗪骈喜树碱衍生物及其制备方法和用途
CN100592871C (zh) * 2008-03-14 2010-03-03 浙江林学院 一种杀虫剂组合物及其加工方法
ES2373172B1 (es) * 2010-07-16 2012-12-10 Consejo Superior De Investigaciones Científicas (Csic) Proceso de obtención de derivados solubles en agua de 20 (s) camptotecina como agentes antitumorales.
US20140086975A1 (en) 2010-10-15 2014-03-27 Rutgers, The State University Of New Jersey Hydrogel formulation for dermal and ocular delivery
CN103313992B (zh) * 2011-01-12 2016-04-27 天堃医药科技（杭州）有限公司 具有hdac抑制作用的喜树碱衍生物
US20190343828A1 (en) * 2018-04-06 2019-11-14 Seattle Genetics, Inc. Camptothecin peptide conjugates
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CN110590796B (zh) * 2018-06-12 2022-07-15 青岛海洋生物医药研究院股份有限公司 喜树碱衍生物及其制备方法和应用
AU2022330892A1 (en) * 2021-08-19 2024-03-21 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Camptothecin derivative, and pharmaceutical composition and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells

Also Published As

Publication number Publication date
CA2081580A1 (en) 1993-04-30
IS3936A (is) 1993-04-30
JP2000109475A (ja) 2000-04-18
CZ323792A3 (en) 1993-10-13
OA09767A (en) 1993-11-30
IS1708B (is) 1998-12-16
HU217970B (hu) 2000-05-28
EP0540099A1 (en) 1993-05-05
JPH05222048A (ja) 1993-08-31
GR3020120T3 (en) 1996-08-31
SK279298B6 (sk) 1998-09-09
CN1072683A (zh) 1993-06-02
IL103571A0 (en) 1993-03-15
DE69209969T2 (de) 1996-09-12
IL103571A (en) 1998-01-04
FI104373B (fi) 2000-01-14
FI924878A0 (fi) 1992-10-28
FI20021090A (fi) 2002-06-07
HU211349A9 (en) 1995-11-28
FI924878A (fi) 1993-04-30
ATE136898T1 (de) 1996-05-15
NZ244914A (en) 1995-01-27
HU9203384D0 (en) 1993-01-28
AP306A (en) 1994-01-28
AP9200439A0 (en) 1992-10-31
DK0540099T3 (da) 1996-06-17
JP3020760B2 (ja) 2000-03-15
SK323792A3 (en) 1998-09-09
MX9206211A (es) 1993-05-01
ES2086643T3 (es) 1996-07-01
DE69209969D1 (de) 1996-05-23
KR100246154B1 (ko) 2000-04-01
MY108261A (en) 1996-09-30
FI982185A0 (fi) 1998-10-08
FI982185A (fi) 1998-10-08
NO924158D0 (no) 1992-10-28
JP3229298B2 (ja) 2001-11-19
AU657007B2 (en) 1995-02-23
EP0540099B1 (en) 1996-04-17
AU2738592A (en) 1993-05-06
CZ284023B6 (cs) 1998-07-15
RU2119921C1 (ru) 1998-10-10
HUT65719A (en) 1994-07-28
NO302073B1 (no) 1998-01-19
NO924158L (no) 1993-04-30

Similar Documents

Publication Publication Date Title
TW221994B (zh)
EP0526229A3 (zh)
EP0507397A3 (zh)
EP0520299A3 (zh)
DE4291684T1 (zh)
EP0521165A4 (zh)
DE4290030T1 (zh)
DE4291983T1 (zh)
DE4291721T1 (zh)
DE4291109T1 (zh)
DE4290105T1 (zh)
FR2680720B1 (zh)
FR2673645B1 (zh)
DE4290953T1 (zh)
FR2676255B1 (zh)
FR2672232B1 (zh)
FR2675155B1 (zh)
CN3009787S (zh)
EP0516217A3 (zh)
EP0522674A3 (zh)
AU7116791A (zh)
AU1515892A (zh)
AU1319292A (zh)
CN3009771S (zh)
AU7128691A (zh)